ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
AstraZeneca divests Atacand commercial rights to Cheplapharm pharmaceutical-technology.
January 06, 2021AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus in over 70 countries to German pharmaceutical firm Cheplapharm Arzneimittel. -
AstraZeneca to Sell Atacand, Atacand Plus Commercial Rights to Cheplapharm americanpharmaceuticalreview
November 06, 2020AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in around 70 countries globally to Cheplapharm Arzneimittel GmbH. -
Atacand to be divested to Cheplapharm in Europe
worldpharmanews
July 25, 2018AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in Europe to Cheplapharm Arzneimittel GmbH (Cheplapharm). Atacand is a presc
Pharma Sources Insight July 2025
